Claims
- 1. A method of inhibiting tumor growth in the brain of a host, comprising administering to the host in need of such an inhibition a therapeutically effective amount of an integrin antagonist which is selected from the group consisting of an antibody against αvβ3, an antibody against αvβ5 and a combination of antibodies respectively against αvβ3 and αvβ5.
- 2. The method of claim 1, wherein the antagonist is a monoclonal antibody immunospecific for αvβ3.
- 3. The method of claim 2, wherein the monoclonal antibody has the immunoreaction characteristics of a monoclonal antibody designated LM-609.
- 4. The method of claim 1, wherein the combination of the antibodies respectively against αvβ3 and αvβ5 is a combination of a monoclonal antibody immunospecific to αvβ3 and a monoclonal antibody immunospecific to αvβ5.
- 5. The method of claim 4, wherein the monoclonal antibody immunospecific to αvβ3 has the immunoreaction characteristics of a monoclonal antibody designated LM-609 and the monoclonal antibody immunospecific to αvβ5 has the immunoreaction characteristics of a monoclonal antibody designated P1-F6.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a division of U.S. patent application Ser. No. 09/489,391 filed on Jan. 21, 2000, now U.S. Pat. No. 6,521,593, which application claims the benefit of U.S. Provisional Patent Application Serial No. 60/118,126 filed on Feb. 1, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60118126 |
Feb 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09489391 |
Jan 2000 |
US |
Child |
10369369 |
Feb 2003 |
US |